ABAXIS (NASDAQ: ABAX) is one of 82 publicly-traded companies in the “Advanced Medical Equipment & Technology” industry, but how does it weigh in compared to its competitors? We will compare ABAXIS to similar businesses based on the strength of its risk, earnings, analyst recommendations, dividends, valuation, profitability and institutional ownership.

Analyst Recommendations

This is a breakdown of recent ratings and recommmendations for ABAXIS and its competitors, as provided by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
ABAXIS 1 4 1 0 2.00
ABAXIS Competitors 253 1814 3258 105 2.59

ABAXIS currently has a consensus price target of $48.63, indicating a potential upside of 5.94%. As a group, “Advanced Medical Equipment & Technology” companies have a potential downside of 6.65%. Given ABAXIS’s higher possible upside, equities analysts clearly believe ABAXIS is more favorable than its competitors.

Earnings and Valuation

This table compares ABAXIS and its competitors gross revenue, earnings per share and valuation.

Gross Revenue EBITDA Price/Earnings Ratio
ABAXIS $227.78 million $49.81 million 32.55
ABAXIS Competitors $2.02 billion $430.74 million -69.00

ABAXIS’s competitors have higher revenue and earnings than ABAXIS. ABAXIS is trading at a higher price-to-earnings ratio than its competitors, indicating that it is currently more expensive than other companies in its industry.

Institutional & Insider Ownership

97.2% of ABAXIS shares are held by institutional investors. Comparatively, 53.0% of shares of all “Advanced Medical Equipment & Technology” companies are held by institutional investors. 4.3% of ABAXIS shares are held by company insiders. Comparatively, 17.2% of shares of all “Advanced Medical Equipment & Technology” companies are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Profitability

This table compares ABAXIS and its competitors’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
ABAXIS 14.12% 10.85% 9.44%
ABAXIS Competitors -327.91% -35.29% -12.43%

Risk & Volatility

ABAXIS has a beta of 0.82, indicating that its share price is 18% less volatile than the S&P 500. Comparatively, ABAXIS’s competitors have a beta of 0.89, indicating that their average share price is 11% less volatile than the S&P 500.

Dividends

ABAXIS pays an annual dividend of $0.56 per share and has a dividend yield of 1.2%. ABAXIS pays out 39.7% of its earnings in the form of a dividend. As a group, “Advanced Medical Equipment & Technology” companies pay a dividend yield of 0.9% and pay out 26.3% of their earnings in the form of a dividend.

Summary

ABAXIS competitors beat ABAXIS on 8 of the 15 factors compared.

About ABAXIS

Abaxis, Inc. is a developer, manufacturer and marketer of portable blood analysis systems that are used in medical specialties in human or veterinary patient care to provide clinicians with blood constituent measurements. The Company markets and sells its products around the world through independent distributors and direct sales force. The Company’s segments are the medical market and the veterinary market. The Company’s medical market products include Piccolo chemistry analyzers and consumable products. The Company develops, manufactures and sells the Piccolo Xpress chemistry analyzer for use in human patient care to provide clinicians with blood constituent measurements. The Company’s veterinary market product offerings include VetScan chemistry analyzers and veterinary reagent discs, VetScan hematology instruments and related reagent kits, VetScan VSpro specialty analyzers and related consumables, VetScan i-STAT analyzers and related consumables and VetScan rapid tests.

Receive News & Ratings for ABAXIS Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ABAXIS Inc. and related companies with MarketBeat.com's FREE daily email newsletter.